Science Corporation announced on November 17, 2026 that it raised a $400 million Series D to expand availability of its PRIMA retinal implant in Europe, prepare for a US launch, and increase investment in its biohybrid neural-interface program. Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech participated, among other investors. The round brings total capital raised since Science’s founding in 2021 to more than $900 million. The company…
Read the original article:
Science Corporation Raises $400M Series D to Expand PRIMA Access
